Locations
Conditions
Treatments
Institutions
Resources
For researchers
About us
Clinical trials
Phase 3, Open-label, Single-dose Study of CSL222 in Adolescent Male Subjects (≥ 12 to < 18 Years of Age) With Severe or Moderately Severe Hemophilia B
Apply
CSL222
Phase 3, Open-label, Single-dose Study of CSL222 in Adolescent Male Subjects (≥ 12 to < 18 Years of Age) With Severe or Moderately Severe Hemophilia B
Basic information
Step 1/5
Provide your basic information
Age
ZIP code
Back
Next step